Abstract
The serotonin uptake inhibitor fluvoxamine was assessed in treatment of alcohol-induced Korsakoff's syndrome (KS) using fixed (4 weeks, 200 mg/day) or individualized (6 weeks, plasma concentration > or = 400 ng/ml) dosing in randomized placebo-controlled double-blind crossover studies. Cognitive functions and concentrations of the major cerebrospinal fluid (CSF) metabolites of serotonin (5-HIAA), norepinephrine (MHPG), and dopamine (HVA) were determined in abstinent, nondepressed KS patients (aged 45-75), at baseline and placebo (3-4 weeks), and after 3-4 (n = 10) or 6 (n = 4) weeks of fluvoxamine administration. Fluvoxamine decreased CSF 5-HIAA compared to placebo (P < 0.003) without consistent changes in HVA or MHPG. Reductions in 5-HIAA correlated with improvements on the Wechsler Memory Scale Memory Quotient (P < 0.05), independent of effects on attention/vigilance or Beck Depression Inventory scores. Reductions in 5-HIAA correlated with plasma fluvoxamine (P < 0.03) only for fluvoxamine concentrations below 450 ng/ml. These findings suggest improvement of memory consolidation and/or retrieval in patients with Korsakoff's syndrome by fluvoxamine via serotonergic mechanisms.
References
Aug 1, 1977·British Journal of Pharmacology·V ClaassenP Placheta
Oct 1, 1978·Journal of Clinical Psychology·G P Prigatano
Jan 1, 1986·Progress in Neuro-psychopharmacology & Biological Psychiatry·P R MartinM J Eckardt
Jan 1, 1986·European Journal of Clinical Pharmacology·H V Curran, M Lader
Mar 1, 1986·Alcoholism, Clinical and Experimental Research·M J Eckardt, P R Martin
May 1, 1983·Analytical Biochemistry·M ScheininM Linnoila
Jul 29, 1983·Science·H WeingartnerM Linnoila
Jan 1, 1983·British Journal of Clinical Pharmacology·W H WilsonT A Ban
Mar 1, 1984·Psychiatry Research·H WeingartnerP A LeWitt
Aug 8, 1980·Journal of Chromatography·G J de Jong
Jul 22, 1983·Science·H WeingartnerP R Martin
Jul 1, 1980·Memory & Cognition·G M Kleiman
Mar 1, 1981·Brain : a Journal of Neurology·W A Lishman
May 1, 1993·Psychological Medicine·S M Stahl
Mar 1, 1993·Clinical Pharmacokinetics·J van Harten
Aug 26, 1998·Electroencephalography and Clinical Neurophysiology·E Amenedo, F Díaz
Sep 1, 1959·Journal of Experimental Psychology·L R PETERSON, M J PETERSON
Aug 1, 1948·Journal of Experimental Psychology·D A GRANT, E A BERG
Citations
Dec 5, 2009·Journal of Neural Transmission·Raffaele NardoneStefan Golaszewski
May 11, 2005·General Hospital Psychiatry·Shusuke NumataTetsuro Ohmori
Aug 1, 1996·Alcoholism, Clinical and Experimental Research·R Z LittenJ Fertig
Mar 19, 2008·The International Journal of Neuropsychopharmacology·Younghoon CheonDai-Jin Kim
Nov 16, 2013·TheScientificWorldJournal·Raffaele NardoneFrancesco Brigo
Sep 11, 2004·Journal of Psychopharmacology·A R Lingford-HughesUNKNOWN British Association for Psychopharmacology
Nov 16, 2007·Journal of Geriatric Psychiatry and Neurology·John O Brooks, Jennifer C Hoblyn
Mar 20, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·T ReusterJ Oehler
Aug 26, 2020·Psychological Medicine·Elsa CaballeriaHugo López-Pelayo
Nov 5, 2005·Neuroscience and Behavioral Physiology·Yu P Sivolap
Jan 17, 2015·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·A E BobrovA A Kursakov
Mar 6, 2021·Neuroscience and Biobehavioral Reviews·Nicolaj MistarzAngelina Isabella Mellentin